{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:44:44Z","timestamp":1778521484615,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.clinthera.2012.08.011","type":"journal-article","created":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T19:59:38Z","timestamp":1349121578000},"page":"2039-2050","source":"Crossref","is-referenced-by-count":47,"title":["Vismodegib and the Hedgehog Pathway: A New Treatment for Basal Cell Carcinoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Frank","family":"Cirrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy S.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.08.011_bib4","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1524-4725.2009.01236.x","article-title":"Review of the hair follicle origin hypothesis for basal cell carcinoma","volume":"35","author":"Donovan","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clinthera.2012.08.011_bib5","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1172\/JCI46307","article-title":"Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations","volume":"121","author":"Grachtchouk","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2012.08.011_bib6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2012.08.011_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/archdermatol.2010.19","article-title":"Incidence estimate of nonmelanoma skin cancer in the United States, 2006","volume":"146","author":"Rogers","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/archdermatol.2010.4","article-title":"Prevalence of a history of skin cancer in 2007: results of an incidence-based model","volume":"146","author":"Stern","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.294.6.681","article-title":"Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years","volume":"294","author":"Christenson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.08.011_bib10","first-page":"20","article-title":"Nonsurgical innovations in the treatment of nonmelanoma skin cancer","volume":"3","author":"Amini","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib11","first-page":"650258","article-title":"Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease","author":"G\u00f6ppner","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.clinthera.2012.08.011_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:CANC.0000031775.04618.30","article-title":"Aggressive basal cell carcinoma: presentation, pathogenesis, and management","volume":"23","author":"Walling","year":"2004","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.clinthera.2012.08.011_bib13","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMe1202170","article-title":"Oral hedgehog-pathway inhibitors for basal-cell carcinoma","volume":"366","author":"Lear","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.08.011_bib14","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1113538","article-title":"Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome","volume":"366","author":"Tang","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.08.011_bib15","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1158\/1078-0432.CCR-09-2570","article-title":"The role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment","volume":"16","author":"Caro","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJMoa0902903","article-title":"Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449","volume":"361","author":"Rudin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.08.011_bib17","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1200\/JCO.2010.27.9943","article-title":"Clinical experience with Hedgehog pathway inhibitors","volume":"28","author":"Low","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ctrv.2010.12.002","article-title":"Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer","volume":"37","author":"Ganti","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clinthera.2012.08.011_bib19","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-10-2745","article-title":"Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1758834010366430","article-title":"Targeting the Hedgehog pathway in cancer","volume":"2","author":"Gupta","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OTT.S21957","article-title":"Hedgehog pathway as a drug target: smoothened inhibitors in development","volume":"5","author":"Lin","year":"2012","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clinthera.2012.08.011_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1158\/0008-5472.CAN-10-2876","article-title":"Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance","volume":"71","author":"Dijkgraaf","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib23","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJMoa0905360","article-title":"Inhibition of the hedgehog pathway in advanced basal-cell carcinoma","volume":"361","author":"Von Hoff","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.08.011_bib24","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.08.011_bib25","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-10-2736","article-title":"Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding","volume":"17","author":"Graham","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib26","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1158\/1078-0432.CCR-11-0972","article-title":"Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors","volume":"17","author":"Lorusso","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2125.2012.04281.x","article-title":"Single- and multiple-dose intravenous and oral pharmacokinetics of the Hedgehog pathway inhibitor vismodegib in healthy female subjects","author":"Graham","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e13106","article-title":"Evaluation of food effect on pharmacokinetics (PK) of GDC-0449 (G) in advanced solid tumor patients","author":"Sharma","year":"2012"},{"key":"10.1016\/j.clinthera.2012.08.011_bib29","series-title":"Erivedge","year":"2012"},{"key":"10.1016\/j.clinthera.2012.08.011_bib30","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-11-B188","article-title":"Pharmacokinetic assessment of drug-drug interaction potential when rosiglitazone or combined oral contraceptive is coadministered with vismodegib in patients with locally advanced or metastatic solid tumors","author":"Lorusso","year":"2011"},{"key":"10.1016\/j.clinthera.2012.08.011_bib31","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1124\/dmd.111.039339","article-title":"A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry","volume":"39","author":"Graham","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"18S","key":"10.1016\/j.clinthera.2012.08.011_bib32","article-title":"A phase I pharmacokinetic trial of sonic hedgehog (SHH) antagonist GDC-0449 in pediatric patients with recurrent or refractory medulloblastoma","volume":"28","author":"Gajjar","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.08.011_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8579","article-title":"Efficacy and safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update","author":"Sekulic","year":"2012"},{"key":"10.1016\/j.clinthera.2012.08.011_bib35","doi-asserted-by":"crossref","first-page":"888","DOI":"10.6004\/jnccn.2010.0066","article-title":"The economic impact of non-melanoma skin cancer: a review","volume":"8","author":"Mudigonda","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2012.08.011_bib36","first-page":"1167","article-title":"Surgical treatment of nonmelanoma skin cancer in the Medicare population","volume":"29","author":"Manternach","year":"2003","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clinthera.2012.08.011_bib37","article-title":"FDA approves drug for an advanced skin cancer","author":"Pollack","year":"2012","journal-title":"New York Times"},{"key":"10.1016\/j.clinthera.2012.08.011_bib38","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-10-3370","article-title":"Targeting superficial or nodular basal cell carcinoma with topically formulated small molecule inhibitor of smoothened","volume":"17","author":"Tang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.08.011_bib39","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-11-2509","article-title":"Molecular pathways: the Hedgehog signaling pathway in cancer","author":"McMillan","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200522X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181200522X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T10:55:25Z","timestamp":1594724125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181200522X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S014929181200522X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}